Nauck MA, Tuttle KR, Tschop MH, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892–908.

Article  PubMed  CAS  Google Scholar 

American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes–2026. Diabetes Care. 2026;49(Suppl 1):S166–82.

Article  Google Scholar 

Syed YY. Tirzepatide: first approval. Drugs. 2022;82(11):1213–20.

Article  PubMed  CAS  Google Scholar 

Shirley M. Mazdutide: first approval. Drugs. 2025;85(12):1621–7.

Article  PubMed  Google Scholar 

Sciwind Biosciences. Sciwind Biosciences announces ecnoglutide injection approved by China’s National Medical Products Administration (NMPA) for chronic weight management [media release]. 06 Mar 2026. https://www.sciwindbio.com/portal/index/newsdetail/id/125/category_id/5.html.

Sciwind Biosciences. Sciwind Biosciences announces ecnoglutide injection approved by China’s National Medical Products Administration (NMPA) for adult type 2 diabetes [media release]. 30 Jan 2026. https://www.sciwindbio.com/portal/index/newsdetail/id/122/category_id/5.html.

Pfizer. Ecnoglutide injection for long-term weight management: Chinese prescribing information [Chinese]. 2026. https://pfizermedicalinformation.cn/srd/download-document/a0rbi00000oDwnrAAC. Accessed 19 May 2026.

Pfizer. Ecnoglutide injection for type 2 diabetes: Chinese prescribing information [Chinese]. 2026. https://pfizermedicalinformation.cn/srd/download-document/a0rbi00000kCN6VAAW. Accessed 05 Jun 2026.

Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide—a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023;75:101762.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tan TMM. Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues? Lancet Diabetes Endocrinol. 2025;13(9):728–30.

Article  PubMed  CAS  Google Scholar 

Sciwind Biosciences. Sciwind Biosciences and HK inno.N Corporation announce licensing and partnership agreement for ecnoglutide injection (XW003) in South Korea [media release]. 07 May 2024. https://www.sciwindbio.com/portal/index/newsdetail/id/101/category_id/5.html.

Sciwind Biosciences. Sciwind Biosciences announces global licensing and collaboration agreement for metabolic disease portfolio [media release]. 10 Jan 2025. https://www.sciwindbio.com/portal/index/newsdetail/id/98/category_id/5.html.

Sciwind Biosciences. Sciwind Biosciences partners with Pfizer China to commercialize its biased GLP-1 in China [media release]. 24 Feb 2026. https://www.sciwindbio.com/portal/index/newsdetail/id/123/category_id/5.html.

Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024;15(1):8408.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhu D, Wang W, Tong G, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026;17(1):1420.

Article  PubMed  PubMed Central  Google Scholar 

He Y, Mi N, Cheng Z, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(10):863–73.

Article  PubMed  CAS  Google Scholar 

Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(9):777–89.

Article  PubMed  CAS  Google Scholar 

Zhu Z, Li Y, Zheng Q, et al. An open-label, active-controlled phase 2 evaluation of novel GLP-1 analog ecnoglutide in adults with obesity. Diabetes. 2023;72(Suppl 1):79–LB.